U.S. SECURITIES AND EXCHANGE COMMISSION
                        Washington, D.C. 20549

            Form 10-QSB - Quarterly or Transitional Report
            (Added by 34-30968, eff. 8/13/93, as amended)

(Mark One)
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15 (D) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the quarterly period ended November 30, 2000.

[   ] TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934

For the transition period from ___________________ to ____________________

Commission file number 0-10035

                          LESCARDEN, INC.
--------------------------------------------------------------------------
   (Exact name of small business issuer as specified in its charter)

        NEW YORK                                   13-2538207
-------------------------------                ------------------
(State or other jurisdiction of                (I.R.S. Employer
 incorporation or organization)                Identification No.)

420 LEXINGTON AVENUE, NEW YORK SUITE 212            10170
----------------------------------------       -----------------
(Address of principle executive offices)         (Zip Code)

Issuer's telephone number (212) 687-1050
                          --------------

______________________________________________________________________.
(Former name, former address and former fiscal year, if changed
                          since last report)

     Check whether the issuer (1) filed all reports required to be filed
by Section 13 or 15(d) of the Exchange Act during the past 12 months (or
for such shorter period that the registrant was required to file such
reports), and (2) has been subject to such filing requirements for the
past 90 days.

Yes [X]   No [ ]

State the number of shares outstanding of each of the issuer's classes
of common equity, as of the latest practicable date.

           Class                      Outstanding at November 30, 2000
----------------------------          --------------------------------
Common Stock $.001 par value                     22,369,169

<PAGE>
                            LESCARDEN INC.
                            --------------
<TABLE>
                       CONDENSED BALANCE SHEET
                       -----------------------
<CAPTION>
                                ASSETS
                                ------
                                                            November 30, 2000       May 31, 2000
                                                               (UNAUDITED)           (AUDITED)
                                                            -----------------       ------------
<S>                                                         <C>                     <C>
Current Assets:
  Cash                                                      $          48,450       $     43,449
  Accounts receivable                                                    -                71,532
  Inventory                                                            87,300             99,880
                                                            -----------------       ------------
      Total Current Assets                                            135,750            214,861

Deferred Income Tax Asset, net of valuation allowance of
$2,664,000 and $2,581,000 at November 30, 2000 and
May 31, 2000 respectively                                                -                  -

      Total Assets                                          $         135,750       $    214,861
                                                            -----------------       ------------
                                                            -----------------       ------------

          LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIENCY)

Currents Liabilities:
  Accounts payable and accrued expenses                      $        117,806       $    163,213
  Advances from related parties                                       255,000             50,000
                                                             ----------------       ------------
            Total Liabilities                                         372,806            213,213
                                                             ----------------       ------------
Commitments and Contingencies

Stockholders' Equity:
  Convertible Preferred Stock                                           1,840              1,840
   Common Stock                                                        22,369             22,319
   Additional Paid-In Capital                                      15,264,681         15,259,731
   Accumulated Deficit                                            (15,525,946)       (15,282,242)
                                                             ----------------       ------------
      Stockholders' Equity                                           (237,056)             1,648
                                                             ----------------       ------------
     Total Liabilities and Stockholders' Equity (Deficiency) $        135,750       $    214,861
                                                             ----------------       ------------
                                                             ----------------       ------------
See notes to financial statements
</TABLE>
<PAGE>
                            LESCARDEN INC.
<TABLE>

                                                    (UNAUDITED)
                  CONDENSED STATEMENTS OF OPERATIONS
                  ----------------------------------
<CAPTION>
                                       For The Three Months         For the Six Months
                                       Ended November 30,           Ended November 30,
                                       --------------------         ------------------
<S>                                <C>           <C>           <C>            <C>
                                        2000           1999          2000           1999
                                        ----           ----          ----           ----
License fees                       $     -       $   86,500    $     -        $   86,500
Product sales and other                 8,633        20,108        17,921         30,028
                                   ----------    ----------    ----------     ----------
Total Revenues                     $    8,633    $  106,608    $   17,921     $  116,528
                                   ----------    ----------    ----------     ----------
Costs and Expenses:
 Cost of Sales                          6,130        11,710        12,580         18,531
 Salaries - Officer                    38,452        39,804        77,680         79,032
 Salaries - Office                      4,670         4,432        11,141         16,091
 Professional Fees and Consulting      29,331        25,366        60,022         69,824
 Research and Development              13,946         6,538        13,946         14,919
 Rent and Office Expenses              28,482        26,081        51,003         50,979
 Travel and Meetings                   14,169         2,081        19,500          9,831
 Taxes - Other                             41          -              458            680
 Insurance                              1,206           900         1,284            984
 Interest                                -             -              600           -
 Other Administrative Expenses          6,637        25,410        13,411         38,280
                                   ----------    ----------    ----------     ----------
  Total Costs and Expenses            143,064       142,322       261,625        299,151
                                   ----------    ----------    ----------     ----------
  Net (Loss)                       $ (134,431)   $  (35,714)   $ (243,704)    $ (182,623)
                                   ----------    ----------    ----------     ----------
                                   ----------    ----------    ----------     ----------
  Net (Loss) Per Share             $     (.01)   $    (.002)   $     (.01)    $     (.01)
                                   ----------    ----------    ----------     ----------
                                   ----------    ----------    ----------     ----------
Weighted Average Number of
  Common Shares Outstanding        22,369,169    21,800,169    22,344,169     21,775,169
                                   ----------    ----------    ----------     ----------
                                   ----------    ----------    ----------     ----------

See notes to financial statements

</TABLE>
<PAGE>
                            LESCARDEN INC.
<TABLE>

                                               (UNAUDITED)
                  CONDENSED STATEMENTS OF CASH FLOWS
<CAPTION>
                                                             For the Six Months Ended
                                                                  November 30,
                                                             ------------------------
<S>                                                    <C>              <C>
                                                             2000              1999
                                                             ----              ----
Cash Flows (Used In) Operations:
  Net (Loss)                                           $ (243,704)      $  (182,623)
  Adjustments to reconcile net income (loss) to net
   cash used in operating activities:
   Changes in operating assets and liabilities:
   Decrease (Increase) in accounts receivable              71,532           (10,500)
   Decrease (Increase) in inventory                        12,580           (25,763)
   Decrease in prepaid expenses                              -               36,000
   Decrease in security deposit                              -                3,080
  (Decrease) in unearned revenue                             -              (43,250)
  (Decrease) in accounts payable and
   accrued expenses                                       (40,407)          (66,928)
                                                       ----------       -----------
  Net Cash (Used In) OPERATIONS                          (199,999)         (289,984)
                                                       ----------       -----------
Cash Flows Provided By Financing Activities:
     Advances from related parties                        205,000           167,000
     Proceeds from purchase of common
     stock and exercise of common stock
     purchase warrants                                       -               55,000
                                                       ----------       -----------
Cash Flows Provided By Financing Activities:
                                                          205,000           222,000
                                                       ----------       -----------



(Decrease) increase in cash                                 5,001           (67,984)

 Cash - Beginning of period                                43,449            91,525
                                                       ----------       -----------
Cash - End of period                                   $   48,450       $    23,541
                                                       ----------       -----------
                                                       ----------       -----------
See notes to financial statements
</TABLE>
<PAGE>
                        LESCARDEN INC.
                        --------------
                                                       (UNAUDITED)
                    NOTES TO FINANCIAL STATEMENTS      -----------
                    -----------------------------
                          November 30, 2000
                          -----------------
Note 1 - General:

       The accompanying unaudited financial statements include all adjustments
which are, in the opinion of management, necessary for a fair statement of
the results for the interim periods. The statements have been prepared in
accordance with the requirements for Form 10-QSB and, therefore, do not
include all disclosures or financial details required by generally accepted
accounting principles. These condensed financial statements should be read in
conjunction with the financial statements and the notes thereto included in
the Company's Annual Report on Form 10-KSB for the year ended May 31, 2000.


       The results of operations for the interim periods are not necessarily
indicative of results to be expected for a full year's operations.

Note 2 - Inventory:

       Inventory at November 30, 2000 consists of the following:

                    Finished Goods       $      86,300
                    Raw Materials                1,000
                                         -------------
                                         $      87,300
                                         -------------
                                         -------------

<PAGE>
                            LESCARDEN INC.


     Management's Discussion and Analysis of Financial Condition
                      and Results of Operations
     -----------------------------------------------------------
                          November 30, 2000
                          -----------------
Results of Operations
---------------------
Overview
--------
     Since its inception, the Company has primarily devoted its resources to
fund research, drug discovery and development.   In addition, the Company
licenses its technology for commercialization by other companies and in recent
fiscal years, the Company began sales of its proprietary bovine cartilage
material, BIO-CARTILAGE<F1>, as a food supplement, and direct sales to
consumers of a line of cosmetic products, which include the Company's
proprietary bovine cartilage material.  In the fiscal year May 31, 2000, the
Company made its initial two commercial shipments of its CATRIX<F1> Wound
Dressing product pursuant to its agreement with ICN IBERICA, S.A., Spain.

     The Company has been unprofitable to date and may continue to incur
operating losses in the foreseeable future. The Company has sustained net
losses of approximately $15.5 million from inception to November 30, 2000.
The Company has primarily financed its research and development activities
through a public offering of Common Stock, private placements of debt and
equity securities, and in recent years, revenues from licensing fees and
product sales.

Three months and six months ended November 30, 2000 compared to the three
months and six months ended November 30, 1999.
-------------------------------------------------------------------------

     The Company's revenues from Product sales and other in the periods
were primarily from the direct sales to consumers of a line of cosmetic
products, which include the Company's proprietary bovine cartilage material,
which commenced in the fiscal year end May 31, 2000.  In the quarter ended
November 30, 1999 the Company earned an $86,500 license fee pursuant to the
Company's agreement with ICN IBERICA, S.A. (see below).

     Total costs and expenses during the six months ended November 30, 2000
were 13% lower than those of the comparative period of the prior year
principally due to lower office salaries, cost of sales, professional fees
and consulting and other administrative expenses.

Liquidity and Capital Resources
-------------------------------

<PAGE>

Overview
--------
     The Company has had losses from operations in each of the five years
ended May 31, 2000.  This trend may continue in the foreseeable future.
Working capital has been provided since the Company's inception primarily
from the sale of equity securities or from borrowings from its officers,
directors and shareholders and from outside investors, and in more recent
quarters, from revenues from licensing fees and product sales.

Present Liquidity
-----------------
     The Company's present liquidity position is critical.  As of November 30,
2000 the Company's total liabilities exceeded its total assets by $ 237,056.
The Company will require additional product sales or funding during, or
shortly after the end of,  the current fiscal quarter ending February 28, 2001
, to sustain its operations.

     As a result of the history of losses incurred by the Company, the net
loss during the year ended May 31, 2000 of ($ 606,086), and the limited
amount of funds currently available to finance the Company's operations,
the report of the Company's independent Certified Public Accountants on the
Company's Financial Statements as of May 31, 1999 and 2000 contain an
explanatory paragraph indicating that the Company may be unable to continue
in existence.

     The Company's licensee of its CATRIX<F1> product, in powder form only,
for topical wound healing purposes (see below) received its initial two
shipments from the Company in the year ended May 31,2000.  In addition, the
Company continued to sell a line of cosmetic products and plans to continue
to implement plans to sell BIO-CARTILAGE<F1> to the over-the-counter food
supplement market. If the Company's efforts to increase revenues are
successful, the Company may increase cash flow in order to allow the Company
to meet its obligations and sustain its operations.  The Company also plans
to try to obtain financing from additional advances from stockholders and
sales of unregistered shares of common stock.

     On March 16, 1999, the Company announced that it had entered into an
agreement with ICN IBERICA, S.A. ("ICNI", a wholly owned subsidiary of ICN
Pharmaceuticals, USA) of Barcelona, Spain whereby ICNI acquired the
semi-exclusive rights to distribute and market the Company's CATRIX<F1> WOUND
CARE DRESSING in Spain for a period of ten years.  Implementation of this
Agreement was contingent upon securing marketing approval for the product by
the Spanish Health Ministry.

<PAGE>

     On September 13, 1999, the Company announced that its CATRIX<F1> Wound
Dressing product was granted full marketing approval by the Spanish Health
Ministry of Madrid.  Under the prevailing regulations of the European Union
("EU"), of which Spain is a member, a drug/device approval in one member
country renders the product marketable in all member states.  Therefore,
CATRIX<F1> Wound Dressing may now be sold throughout the 15 countries of the
EU.

     The Company is currently awaiting the establishment of a reimbursement
rate by the Spanish Health Ministry for CATRIX<F1> Wound Dressing, which is
the equivalent to the FDA's HICFA agency that reimburses under medicare and
medicaid.  This will determine how much the Spanish government will pay for
retirees and the working public in Spain for their use of CATRIX<F1> Wound
Dressing. While there is no assurance that a reimbursement rate will be
awarded, a favorable rate may be a material factor in determining sales growth
of the product in Spain.

    The Company has no material commitments for capital expenditures at
November 30, 2000.

<F1>
A registered trademark of Lescarden Inc.

<PAGE>

                            LESCARDEN INC.
                            --------------
                     Part II - Other Information
                     ---------------------------
Item 6.  Exhibits and Reports on Form 8-K
-----------------------------------------
       (a) Exhibits: EX-27

       (b) Reports on Form 8-K: There were no reports on Form 8-K filed for
           the three months ended November 30, 2000.

                          INDEX TO EXHIBITS
27-Financial Data Schedule

<PAGE>

                              Signatures
                              ----------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned there unto duly authorized.





                               LESCARDEN INC.
                               --------------
                               (Registrant)




Date: January 8, 2001  s/Gerard A. Dupuis
                       -----------------------
                       Gerard A. Dupuis
                       Chairman of the Board
                       Chief Executive Officer